Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker MIRM · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Expanded-Access Program for the Treatment of Chronic Hepatitis D With Brelovitug NCT07922733 · Chronic Hepatitis, Delta Virus Brelovitug | MIRM Mirum Pharmaceuticals, Inc. | — | Available | — | — | Registry ↗ |
| Nov 13, 2026 | Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) NCT06553768 · Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) Maralixibat, Placebo | MIRM Mirum Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 90 | Jul 29, 2026 | Registry ↗ |
| Nov 13, 2026 | Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US) NCT06193928 · Alagille Syndrome, Progressive Familial Intrahepatic Choles… Livmarli, Livmarli | MIRM Mirum Pharmaceuticals, Inc. | — | Recruiting | 70 | Sep 20, 2028 | Registry ↗ |
| Oct 27, 2026 | Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevi… NCT07454837 · Chronic Hepatitis D Brelovitug (BJT-778), Bulevirtide | MIRM Mirum Pharmaceuticals, Inc. | Phase 2/3 | Recruiting | 120 | Aug 31, 2027 | Registry ↗ |
| Oct 27, 2026 | A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infect… NCT06907290 · Chronic Hepatitis D Infection Brelovitug 300 mg, Brelovitug 900 mg | MIRM Mirum Pharmaceuticals, Inc. | Phase 2/3 | Active, not recruiting | 150 | May 2029 | Registry ↗ |
| Oct 19, 2026 | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With… NCT04663308 · Primary Sclerosing Cholangitis Volixibat, Placebo | MIRM Mirum Pharmaceuticals, Inc. | Phase 2 | Active, not recruiting | 182 | Feb 20, 2026 | Registry ↗ |
| Oct 8, 2026 | A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta… NCT07200908 · Chronic Hepatitis D Infection Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mg | MIRM Mirum Pharmaceuticals, Inc. | Phase 3 | Recruiting | 172 | Jun 30, 2027 | Registry ↗ |
| Oct 7, 2026 | A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379 NCT07712718 · Healthy Volunteers [14C]-MRM-3379 | MIRM Mirum Pharmaceuticals, Inc. | Phase 1 | Completed | 7 | Jul 8, 2026 | Registry ↗ |
| Sep 29, 2026 | Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) NCT07209462 · Fragile X Syndrome Low dose of MRM-3379, Middle Dose of MRM-3379 | MIRM Mirum Pharmaceuticals, Inc. | Phase 2 | Recruiting | 60 | Oct 2027 | Registry ↗ |
| Sep 16, 2026 | MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With… NCT07823127 · Intrahepatic Cholestasis of Pregnancy Maralixibat | MIRM Mirum Pharmaceuticals, Inc. | Phase 2 | Not yet recruiting | 15 | Jan 12, 2029 | Registry ↗ |
| Aug 25, 2026 | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With… NCT05050136 · Primary Biliary Cholangitis, PBC Volixibat, Placebo | MIRM Mirum Pharmaceuticals, Inc. | Phase 2 | Active, not recruiting | 333 | Jan 2027 | Registry ↗ |
| Jul 31, 2026 | The REPLACE Registry for Cholbam® (Cholic Acid) NCT03115086 · Bile Acid Synthesis Disorders Cholbam | MIRM Mirum Pharmaceuticals, Inc. | — | Active, not recruiting | 55 | Jul 2038 | Registry ↗ |
| Jun 29, 2026 | A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Inf… NCT07298330 · Chronic Hepatitis D Infection Brelovitug 300 mg, Brelovitug 900 mg | MIRM Mirum Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 80 | Aug 2026 | Registry ↗ |
| Jun 23, 2026 | Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients Wit… NCT07290257 · Alagille Syndrome, Progressive Familial Intrahepatic Choles… Livmarli Oral Product | MIRM Mirum Pharmaceuticals, Inc. | Phase 4 | Recruiting | 230 | Sep 22, 2030 | Registry ↗ |
| Jun 23, 2026 | An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (P… NCT04185363 · Progressive Familial Intrahepatic Cholestasis (PFIC) Maralixibat | MIRM Mirum Pharmaceuticals, Inc. | Phase 3 | Completed | 84 | Apr 23, 2025 | Registry ↗ |
| Jun 2, 2026 | A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholesta… NCT04729751 · Progressive Familial Intrahepatic Cholestasis, Alagille Syn… Maralixibat | MIRM Mirum Pharmaceuticals, Inc. | Phase 2 | Completed | 27 | Dec 17, 2024 | Registry ↗ |
| Dec 8, 2025 | MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in S… NCT04168385 · Cholestatic Liver Disease Maralixibat | MIRM Mirum Pharmaceuticals, Inc. | Phase 2 | Completed | 52 | Sep 4, 2024 | Registry ↗ |
| Mar 19, 2025 | Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai NCT04524390 · Biliary Atresia Maralixibat, Placebo | MIRM Mirum Pharmaceuticals, Inc. | Phase 2 | Completed | 75 | Nov 7, 2023 | Registry ↗ |
| Oct 28, 2024 | Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE) NCT04270682 · CTX Blinded CDCA 250 mg TID, Placebo | MIRM Mirum Pharmaceuticals, Inc. | Phase 3 | Completed | 19 | Jul 13, 2023 | Registry ↗ |
| Aug 6, 2024 | A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With… NCT04718961 · Intrahepatic Cholestasis of Pregnancy Volixibat, Placebo | MIRM Mirum Pharmaceuticals, Inc. | Phase 2 | Terminated | 4 | Dec 7, 2022 | Registry ↗ |
| Dec 11, 2023 | A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial In… NCT03905330 · Progressive Familial Intrahepatic Cholestasis (PFIC) Maralixibat, Placebo | MIRM Mirum Pharmaceuticals, Inc. | Phase 3 | Completed | 93 | Sep 1, 2022 | Registry ↗ |
| Oct 23, 2023 | Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment… NCT02057718 · Progressive Familial Intrahepatic Cholestasis (PFIC) LUM001 (Maralixibat) | MIRM Mirum Pharmaceuticals, Inc. | Phase 2 | Completed | 33 | May 8, 2020 | Registry ↗ |
| Oct 3, 2023 | Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis NCT01438411 · Bile Acid Synthesis Defect Cholic Acid | MIRM Mirum Pharmaceuticals, Inc. | Phase 3 | Completed | 53 | Jul 2016 | Registry ↗ |
| Oct 3, 2023 | Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of… NCT01115582 · Inborn Errors of Bile Acid Synthesis Cholic acid | MIRM Mirum Pharmaceuticals, Inc. | Phase 3 | Completed | 16 | Aug 2010 | Registry ↗ |
| Oct 3, 2023 | Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid NCT00007020 · Infantile Refsum's Disease, Zellweger Syndrome Cholic Acids | MIRM Mirum Pharmaceuticals, Inc. | Phase 3 | Completed | 85 | Dec 2009 | Registry ↗ |
| Nov 19, 2021 | An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treat… NCT02047318 · Alagille Syndrome LUM001 (Maralixibat) | MIRM Mirum Pharmaceuticals, Inc. | Phase 2 | Completed | 19 | Jun 17, 2020 | Registry ↗ |
| Oct 20, 2021 | A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagil… NCT04530994 · Alagille Syndrome maralixibat | MIRM Mirum Pharmaceuticals, Inc. | — | Approved for marketing | — | — | Registry ↗ |
| Jul 14, 2021 | Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants Wit… NCT02160782 · Alagille Syndrome LUM001 (Maralixibat), Placebo | MIRM Mirum Pharmaceuticals, Inc. | Phase 2 | Completed | 31 | May 28, 2020 | Registry ↗ |
| Jul 1, 2021 | An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treat… NCT02117713 · Alagille Syndrome LUM001 (Maralixibat) | MIRM Mirum Pharmaceuticals, Inc. | Phase 2 | Completed | 34 | Jun 1, 2020 | Registry ↗ |
| Nov 25, 2019 | Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) NCT02787304 · Non-Alcoholic Steatohepatitis SHP626, Placebo | MIRM Mirum Pharmaceuticals, Inc. | Phase 2 | Terminated | 197 | Jul 27, 2018 | Registry ↗ |
| May 1, 2019 | A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose NCT02571192 · Non-Alcoholic Steatohepatitis SHP626, 5.95 μCi RAD | MIRM Mirum Pharmaceuticals, Inc. | Phase 1 | Completed | 8 | Oct 1, 2015 | Registry ↗ |
| Apr 4, 2019 | Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and… NCT02475317 · Healthy Volunteers Placebo, Maralixibat | MIRM Mirum Pharmaceuticals, Inc. | Phase 1 | Completed | 84 | Dec 1, 2015 | Registry ↗ |
| Mar 29, 2019 | Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Chol… NCT02061540 · Primary Sclerosing Cholangitis (PSC) LUM001 | MIRM Mirum Pharmaceuticals, Inc. | Phase 2 | Completed | 27 | Feb 2016 | Registry ↗ |
| Mar 28, 2019 | Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With… NCT01903460 · Alagille Syndrome LUM001, Placebo | MIRM Mirum Pharmaceuticals, Inc. | Phase 2 | Completed | 20 | Feb 2015 | Registry ↗ |
| Mar 27, 2019 | Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary… NCT01904058 · PBC, Primary Biliary Cirrhosis LUM001, Placebo | MIRM Mirum Pharmaceuticals, Inc. | Phase 2 | Completed | 66 | Apr 2015 | Registry ↗ |
| Mar 26, 2019 | Safety and Tolerability Study of SHP626 in Overweight and Obese Adults NCT02287779 · Non-Alcoholic Steatohepatitis SHP626, Placebo | MIRM Mirum Pharmaceuticals, Inc. | Phase 1 | Completed | 84 | Jun 19, 2015 | Registry ↗ |
| Mar 26, 2019 | Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome NCT02057692 · Alagille Syndrome LUM001, Placebo | MIRM Mirum Pharmaceuticals, Inc. | Phase 2 | Completed | 37 | Nov 16, 2016 | Registry ↗ |
| Mar 19, 2019 | An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Pr… NCT02321306 · Primary Biliary Cirrhosis LUM001 | MIRM Mirum Pharmaceuticals, Inc. | Phase 2 | Withdrawn | 0 | Dec 2017 | Registry ↗ |
| Mar 18, 2019 | A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial… NCT03353454 · Progressive Familial Intrahepatic Cholestasis (PFIC) Maralixibat, Placebo | MIRM Mirum Pharmaceuticals, Inc. | Phase 3 | Withdrawn | 0 | Jun 15, 2020 | Registry ↗ |
| Mar 18, 2019 | Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease NCT02131623 · Alagille Syndrome, Progressive Familial Intrahepatic Choles… | MIRM Mirum Pharmaceuticals, Inc. | — | Completed | 23 | Mar 2015 | Registry ↗ |
40 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:51 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances